nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»nogr-352Research ArticleОБЗОРREVIEWСИНДРОМ РАЗДРАЖЕННОГО КИШЕЧНИКА: ОБЗОР РИМСКИХ КРИТЕРИЕВ IV С ПОЗИЦИИ РОССИЙСКИХ КЛИНИЦИСТОВIRRITABLE BOWEL SYNDROME: OVERVIEW OF ROME CRITERIA IV FROM THE POINT OF VIEW OF RUSSIAN CLINICIANSСаблинО. А.SablinO. A.noemail@neicon.ruИльчишинаТ. А.IlchishinaT. A.noemail@neicon.ruФГБУ Всероссийский центр экстренной и радиационной медицины им. А. М. Никифорова МЧС России; ГБОУ ВО Северо-Западный государственный медицинский университет им. И. И. Мечникова МЗ РФРоссияThe Federal State Budgetary Institute «The Nikiforov Russian Center of Emergency and Radiation Medicine» EMERCOM of Russia; State budget institution of higher education “North-Western State Medical University named after I. I. Mechnikov” under the Ministry of Public Health of the Russian FederationRussian FederationГБОУ ВО Северо-Западный государственный медицинский университет им. И. И. Мечникова МЗ РФРоссияState budget institution of higher education “North-Western State Medical University named after I. I. Mechnikov” under the Ministry of Public Health of the Russian FederationRussian Federation20162012201601292100Copyright © Саблин О.А., Ильчишина Т.А., 20162016Саблин О.А., Ильчишина Т.А.Sablin O.A., Ilchishina T.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/352

Статья посвящена одному из самых распространенных функциональных расстройств кишечника - синдрому раздраженного кишечника (СРК). В обзоре отражены современные представления о СРК с точки зрения новых диагностических Римских критериев ІV, приводятся их отличия от Римских критериев III пересмотра и подробно изложены критерии диагноза субтипов СРК. Рассмотрены основные методы диагностики данной патологии, особое внимание уделено терапии вариантов СРК в зависимости от ведущего симптома с позиций доказательной медицины. Отмечена клиническая доступность Римских критериев IV для диагностики функциональных расстройств.

The article is dedicated to the one of the most common functional bowel disorders - irritable bowel syndrome (IBS). This overview gives the current understanding of IBS based on the new diagnostic Rome criteria IV and represents the differences from Rome criteria III; there are also detailed diagnostic criteria for IBS subtypes. The main diagnostic methods are reviewed and special attention is paid to therapy of IBS subtypes depending on the leading symptom from the perspective of evidence-based medicine. Clinical availability of Rome criteria IV for diagnostics of functional disorders have been noted.

синдром раздраженного кишечникаРимские критерии IVфункциональные расстройства кишечникакритерии диагностики СРКлечение СРКirritable bowel syndromeRome criteria IVfunctional bowel disordersIBS diagnostic criteriaIBS treatmentReferencesDrossman D. A. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features, and Rome IV. Gastroenterology 2016;150:1262-1279Drossman D. A. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features, and Rome IV. Gastroenterology 2016;150:1262-1279Lacy B. E., Mearin F., Chang L. et al. Bowel Disorders // Gastroenterology. 2016. № 150. Р. 1393-1407.Lacy B. E., Mearin F., Chang L. et al. Bowel Disorders // Gastroenterology. 2016. № 150. Р. 1393-1407.Gaertner J., Siemens W., Camilleri M. et al. Definitions and outcome measures of clinical trials regarding opioidinduced constipation: a systematic review // J Clin Gastroenterol. 2015. № 49. P. 9-16.Gaertner J., Siemens W., Camilleri M. et al. Definitions and outcome measures of clinical trials regarding opioidinduced constipation: a systematic review // J Clin Gastroenterol. 2015. № 49. P. 9-16.Lovell R. M., Ford A. C. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis // Clin Gastroenterol Hepatol. 2012.№ 10. Р. 712-721.Lovell R. M., Ford A. C. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis // Clin Gastroenterol Hepatol. 2012.№ 10. Р. 712-721.Camilleri M., Lasch K., Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome // Am J Physiol Gastrointest Liver Physiol. 2012. № 303. G775-G785.Camilleri M., Lasch K., Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome // Am J Physiol Gastrointest Liver Physiol. 2012. № 303. G775-G785.Drossman D. A. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? // Am J Med. 1999. № 107. Р.41S-50SDrossman D. A. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? // Am J Med. 1999. № 107. Р.41S-50SSpiegel B. M., Bolus R., Agarwal N. et al. Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials // Aliment Pharmacol Ther. 2010. № 32. Р.1275-1291.Spiegel B. M., Bolus R., Agarwal N. et al. Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials // Aliment Pharmacol Ther. 2010. № 32. Р.1275-1291.Whitehead W. E., Palsson O. S. Report on Rome Normative GI Symptom Survey. 2014.Whitehead W. E., Palsson O. S. Report on Rome Normative GI Symptom Survey. 2014.Ford A. C., Bercik P., Morgan D. G. et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care // Gastroenterology. 2013. № 145. Р. 1262-1270.Ford A. C., Bercik P., Morgan D. G. et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care // Gastroenterology. 2013. № 145. Р. 1262-1270.Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testing for differentiating amongst inflammatory and noninflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess 2013;17:1-211.Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testing for differentiating amongst inflammatory and noninflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess 2013;17:1-211.Limsui D, Pardi DS, Camilleri M, et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis 2007;13:175-181.Limsui D, Pardi DS, Camilleri M, et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis 2007;13:175-181.Slattery S. A., Niaz O., Azia Q. et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhea // Aliment Pharmacol Ther. 2015. № 42. Р.3-11.Slattery S. A., Niaz O., Azia Q. et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhea // Aliment Pharmacol Ther. 2015. № 42. Р.3-11.Ford A. C., Moayyedi P., Lacy B. E. et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation // Am J Gastroenterol. 2014. № 109 (1). S2-26.Ford A. C., Moayyedi P., Lacy B. E. et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation // Am J Gastroenterol. 2014. № 109 (1). S2-26.Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebocontrolled trial. Am J Gastroenterol 2011;106:508-514.Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebocontrolled trial. Am J Gastroenterol 2011;106:508-514.Vazquez-Roque MI, Camilleri M, Smyrk T, et al. Acontrolled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology 2013;144:903-911Vazquez-Roque MI, Camilleri M, Smyrk T, et al. Acontrolled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology 2013;144:903-911Halmos E. P., Power V. A., Shepherd S. J. et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome // Gastroenterology. 2014. № 146. Р.67-75.Halmos E. P., Power V. A., Shepherd S. J. et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome // Gastroenterology. 2014. № 146. Р.67-75.Biesiekierski JR, Peters SL, Newnham ED, et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013;145:320-328.Biesiekierski JR, Peters SL, Newnham ED, et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013;145:320-328.Lavo B., Stenstam M., Nielsen A. L. et al. Loperamide in treatment of irritable bowel syndrome - a double-blind placebo controlled study // Scand J Gastroenterol Suppl. 1987. № 130. Р. 77-80.Lavo B., Stenstam M., Nielsen A. L. et al. Loperamide in treatment of irritable bowel syndrome - a double-blind placebo controlled study // Scand J Gastroenterol Suppl. 1987. № 130. Р. 77-80.Efskind P. S., Bernklev T., Vatn M. H. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome // Scand J Gastroenterol. 1996. № 31. Р. 463-468.Efskind P. S., Bernklev T., Vatn M. H. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome // Scand J Gastroenterol. 1996. № 31. Р. 463-468.Bajor A., Tornblom H., Rudling M. et al. Increased colonic bile acid exposure: a relevant risk factor for symptoms and treatment in IBS // Gut. 2015. № 64. Р. 84-92.Bajor A., Tornblom H., Rudling M. et al. Increased colonic bile acid exposure: a relevant risk factor for symptoms and treatment in IBS // Gut. 2015. № 64. Р. 84-92.Chey W. D., Camilleri M., Chang L. et al. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation // Am J Gastroenterol. 2011. № 106. Р.1803-1812.Chey W. D., Camilleri M., Chang L. et al. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation // Am J Gastroenterol. 2011. № 106. Р.1803-1812.O’Mahony L., McCarthy J., Kelly P. et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles // Gastroenterology. 2005. № 128. Р.541-551.O’Mahony L., McCarthy J., Kelly P. et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles // Gastroenterology. 2005. № 128. Р.541-551.Whorwell P. J., Altringer L., Morel J. et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome // Am J Gastroenterol. 2006. № 101. Р. 1581-1590.Whorwell P. J., Altringer L., Morel J. et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome // Am J Gastroenterol. 2006. № 101. Р. 1581-1590.Didari Т. et al. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol. 2015 № 21(10). P. 3072-3084.Didari Т. et al. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol. 2015 № 21(10). P. 3072-3084.Pimentel M., Lembo A., Chey W. D. et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation // N Engl J Med. 2011. № 364. Р. 22-32.Pimentel M., Lembo A., Chey W. D. et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation // N Engl J Med. 2011. № 364. Р. 22-32.Lembo A. J., Lacy B. E., Zuckerman M. J. et al. Eluxadoline treatment for irritable bowel syndrome with diarrhea // N Engl J Med. 2016. № 374. Р. 242-253.Lembo A. J., Lacy B. E., Zuckerman M. J. et al. Eluxadoline treatment for irritable bowel syndrome with diarrhea // N Engl J Med. 2016. № 374. Р. 242-253.Vahedi H., Merat S., Momtahen S. et al. Clinical trial: the effect of amitriptyline in patients with diarrhoeapredominant irritable bowel syndrome // Aliment Pharmacol Ther. 2008. № 27. Р. 678-684.Vahedi H., Merat S., Momtahen S. et al. Clinical trial: the effect of amitriptyline in patients with diarrhoeapredominant irritable bowel syndrome // Aliment Pharmacol Ther. 2008. № 27. Р. 678-684.Ford A. C., Quigley E. M., Lacy B. E. et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis // Am J Gastroenterol. 2014. № 109. Р. 1350-1365.Ford A. C., Quigley E. M., Lacy B. E. et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis // Am J Gastroenterol. 2014. № 109. Р. 1350-1365.Chapman R. W., Stanghellini V., Geraint M. et al. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome // Am J Gastroenterol. 2013. № 108. Р. 1508-1515.Chapman R. W., Stanghellini V., Geraint M. et al. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome // Am J Gastroenterol. 2013. № 108. Р. 1508-1515.Drossman D. A., Chey W. D., Johanson J. F. et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies // Aliment Pharmacol Therapeut. 2009. № 29. Р. 329-341.Drossman D. A., Chey W. D., Johanson J. F. et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies // Aliment Pharmacol Therapeut. 2009. № 29. Р. 329-341.Quigley E. M., Tack J., Chey W. D. et al. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints // Aliment Pharmacol Therapeut. 2013. № 37. Р. 49-61.Quigley E. M., Tack J., Chey W. D. et al. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints // Aliment Pharmacol Therapeut. 2013. № 37. Р. 49-61.Rao A. S., Wong B. S., Camilleri M. et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis // Gastroenterology. 2010. № 139. Р. 1549-1558.Rao A. S., Wong B. S., Camilleri M. et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis // Gastroenterology. 2010. № 139. Р. 1549-1558.Khanna R., MacDonald J.K., Levesque B. G. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis // J Clin Gastroenterol. 2014. № 48. Р.505-512.Khanna R., MacDonald J.K., Levesque B. G. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis // J Clin Gastroenterol. 2014. № 48. Р.505-512.Lee, K.J., Kim, N.Y., Kwon, J.K., et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine // Neurogastroenterol Motil, 2011;23; Р.1098-1104.Lee, K.J., Kim, N.Y., Kwon, J.K., et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine // Neurogastroenterol Motil, 2011;23; Р.1098-1104.Martínez-Vázquez M.A., Vázquez-Elizondo G., González-González J.A., Gutiérrez-Udave R., Maldonado-Garza H.J., Bosques-Padilla F. J. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis // Rev Gastroenterol Mex 2012;77: Р.82-90.Martínez-Vázquez M.A., Vázquez-Elizondo G., González-González J.A., Gutiérrez-Udave R., Maldonado-Garza H.J., Bosques-Padilla F. J. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis // Rev Gastroenterol Mex 2012;77: Р.82-90.

The authors declare that there are no conflicts of interest present.